US Patent

US12545705 — IBAT inhibitors for the treatment of liver diseases

Method of Use · Assigned to Albireo AB · Expires 2031-11-08 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects specific IBAT inhibitors for the treatment of liver diseases, including their compositions, methods of treatment, and kits.

USPTO Abstract

The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

Drugs covered by this patent

Bylvay (ODEVIXIBAT) · Ipsen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay
`U-3186`	—	Bylvay

Patent Metadata

Patent number: US12545705
Jurisdiction: US
Classification: Method of Use
Expires: 2031-11-08
Drug substance claim: No
Drug product claim: No
Assignee: Albireo AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.